IDH2 and astrocytoma (excluding glioblastoma): IDH mutant astrocytomas with CDKN2A/B homozygous deletions have significantly shorter survival (Yeo et al., 2023; Brat et al., 2020; Appay et al., 2019; Alentorn et al., 2015).